Obalon Therapeutics, which is commercializing an intragastric balloon device designed to assist with weight loss, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Obalon Therapeutics plans to list on the Nasdaq under the symbol OBLN. UBS Investment Bank, Canaccord Genuity and Stifel acted as lead managers on the deal.
Obalon Therapeutics prices IPO at $15, within the range
October 5, 2016

